ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 508

Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

Tsutomu Takeuchi1, Yoshiya Tanaka 2, Sakae Tanaka 3, Atsushi Kawakami 4, Yeong-Wook Song 5, Yi-Hsing Chen 6, Mitsuhiro Rokuda 7, Hiroyuki Izutsu 7, Satoshi Ushijima 7, Yuichiro Kaneko 7, Yoshihiro Nakashima 7, Teruaki Shiomi 7 and Emi Yamada 7, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3University of Tokyo, Tokyo, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Seoul National University Hospital, Seoul, Republic of Korea, 6Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 7Astellas Pharma, Inc., Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Janus kinase (JAK) and disease-modifying antirheumatic drugs, rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: RA – Treatments Poster I: Novel Treatments

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and in Phase 3 studies (RAJ3 study [inadequate response to DMARDs], NCT02308163, and RAJ4 study [inadequate response to MTX], NCT02305849). In this long-term interim extension study (NCT01638013), we report the safety and efficacy data for peficitinib (mean treatment exposure, 22.7 months) in patients who previously completed these Phase 2b and 3 studies.

Methods: This multicenter, open-label extension study was conducted in Japan, Korea and Taiwan. All patients had RA previously diagnosed according to 1987 ACR criteria or 2010 ACR/EULAR criteria (RAJ1 study followed 1987 ACR criteria exclusively). Patients received oral peficitinib (50 mg, 100 mg or 150 mg) once daily. The starting dose was 100 mg (RAJ3/4) or 50 mg (RAJ1). Doses could be increased to 150 mg/day or reduced (from 100 mg/day or 150 mg/day) to 50 mg/day according to clinical response and safety assessment, as judged by the investigator. Prior and concomitant administration of study-specific non-biological DMARDs was dependent upon the preceding study. For patients in the RAJ1 study and RAJ3 monotherapy study with peficitinib, administration of DMARDs was prohibited from the end of the assessments to the initiation of administration of peficitinib in this extension study. For the RAJ3/RAJ4 peficitinib combination studies, with DMARDs (including MTX) and MTX, respectively, subjects received the concomitant drug concerned from the termination of study to the initiation of administration of peficitinib and throughout the treatment period in this extension study. Discontinuation of the concomitant drug or alteration of the dose was permitted within the range not exceeding or falling below the baseline dose in the previous study. Efficacy outcomes were assessed in the total patient population and grouped according to their preceding study.

Results: In total, 843 patients received peficitinib: RAJ1, n=201; RAJ3, n=225; RAJ4, n=417. During long-term treatment, ACR20 responses were maintained from baseline for patients receiving maximum doses of 100/150 mg/day, and were improved then maintained in patients receiving maximum doses of 50 mg/day (Figure). ACR components and DAS28-CRP also demonstrated continuous improvements from the baselines of preceding studies. Treatment-emergent adverse events (AEs) were reported in 757 (89.8%) patients (Table), primarily grade 1/2 in severity; the most common were nasopharyngitis, RA and herpes zoster. Rates of AEs of special interest (serious infections, herpes zoster-related disease and malignancies) were greater for patients from RAJ3/4 than RAJ1. There was no evidence to support a trend towards increasing incidence rate/100 patient years with treatment duration. One death during and one death after the study were considered probably and possibly related to study drug, respectively (Table).

Conclusion: This interim analysis after 22.7 months mean treatment exposure demonstrated no additional safety concerns were observed with longer term administration of peficitinib in RA patients, and efficacy was maintained for the study duration.


Disclosure: T. Takeuchi, AbbVie, 2, 5, 8, AbbVie GK, 2, 9, Asahi Kasei, 2, Asahikasei, 2, Asahikasei Pharma Corp., 2, Astellas, 2, 8, 9, Astellas Pharma Inc, 2, Astellas Pharma, Inc., 2, 5, 8, 9, Astra Zeneca, 2, AstraZeneca, 8, AYUMI, 2, 9, AYUMI Pharmaceutical Corporation, 2, BMS, 2, 8, Boehringer-ingelheim, 9, Bristol–Myers K.K., 9, Bristol-Myers, 2, Bristol-Myers Squibb, 8, Chugai, 2, 8, 9, Chugai Pharmaceutical Co, Ltd., 2, Daiichi Sankyo, 2, 8, 9, Daiichi Sankyo Co., Ltd., 2, Eisai, 2, 5, 8, 9, Eisai Co., Ltd., 2, Eli Lilly, 2, 8, Eli Lilly Japan, 9, Gilead Sciences, Inc., 9, GlaxoSmithKline K.K, 9, GSK, 8, Janssen, 2, 8, Janssen Pharmaceutical K.K, 9, Mitsubishi Tanabe, 2, 9, Mitsubishi Tanabe Pharma Co., 2, Mitsubishi-Tanabe Pharma Corp, 2, 8, 9, Nippon Kayaku, 2, Nipponkayaku, 2, 9, Nipponkayaku Co.Ltd., 2, Novartis, 2, 8, Novartis Pharma K.K, 2, 9, Novartis Pharma K.K., 2, Pfizer, 2, 8, Pfizer Japan, 2, 9, Pfizer Japan Inc., 2, Sanofi, 8, Sanofi K.K, 9, Shionogi & Co., 2, Shionogi & Co., LTD., 2, Taiho, 2, 8, 9, Taisho, 9, Taisho Toyama, 2, 8, Takahashi Industrial and Economic Research Foundation, 2, Takeda, 2, 8, Takeda Pharmaceutical Co., Ltd., 2, Teijin, 2, 8, UCB, 8, 9, UCB Japan, 9; Y. Tanaka, Abbvie, 8, AbbVie, 5, 8, Asahi-kasei, 2, Asahi-Kasei, 2, Asahi-kasei, BMS, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, Ono, Pfizer, Sanofi, Takeda, UCB, 2, Astellas, 8, Astellas Pharma, 9, Astellas Pharma, Inc., 2, 3, 5, 8, 9, Astellas, BMS, Chugai, Daiichi-Sankyo, Eli Lilly, Janssen, Mitsubishi-Tanabe, Pfizer, Sanofic, UCB, YL Biologics, 8, BMS, 2, 5, 8, Bristol-Myers, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Daiichi-Sankyo, 2, 8, Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, Abbvie, Pfizer, YL Biologics, Bristol-Myers, 8, Eisai, 2, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 8, Genzyme, 5, Glaxo-Smithkline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, Asahi-kasei, 8, Janssen, 8, Mitsubishi-Tanabe, 2, 8, Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbvie, Astellas, Daiichi-Sankyo, Ono, MSD, Taisho-Toyama., 2, Mitsubishi-Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers, MSD, Astellas, Abbvie, Eisai, 2, Novartis, 8, Ono, 2, Pfizer, 5, 8, Pfizer Inc, 8, Roche, 5, Sanofi, 2, Takeda, 2, 8, Teijin, 8, UCB, 2, YL Biologics, 8; S. Tanaka, Astellas Pharma, Inc., 2, 5, 8, 9; A. Kawakami, Astellas Pharma, Inc., 2, 5, 8, 9; Y. Song, Astellas Pharma, Inc., 9; Y. Chen, Astellas Pharma, Inc., 5, 8, 9; M. Rokuda, Astellas Pharma, Inc., 3, 9; H. Izutsu, Astellas Pharma, Inc., 3, 9; S. Ushijima, Astellas Pharma, Inc., 3, 9; Y. Kaneko, Astellas Pharma, Inc., 3, 9; Y. Nakashima, Astellas Pharma, Inc., 3, 9; T. Shiomi, Astellas Pharma, Inc., 3, 9; E. Yamada, Astellas Pharma, Inc., 3, 9.

To cite this abstract in AMA style:

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y, Chen Y, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Nakashima Y, Shiomi T, Yamada E. Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/longer-term-safety-and-efficacy-of-peficitinib-in-patients-with-rheumatoid-arthritis-after-22-7-months-mean-treatment-exposure-interim-data-from-a-long-term-open-label-extension-study-in-japan-kore/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longer-term-safety-and-efficacy-of-peficitinib-in-patients-with-rheumatoid-arthritis-after-22-7-months-mean-treatment-exposure-interim-data-from-a-long-term-open-label-extension-study-in-japan-kore/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences